Device Trial Radar · NCT07927166
Local Antibiotic Delivery From an Intramedullary Nail After Surgical Treatment of Tibial Fractures at High Risk of Infection
Last checked: Nov 20, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
317
Planned (sponsor's estimate)
Start
Jan 2027
Primary completion
Feb 2029
Study completion Feb 2030
Sponsor
- Lead sponsor
- Reselute, Inc.Not on our public-company list
- Sponsor type
- Industry
- Collaborators
- Major Extremity Trauma Research Consortium
- First posted
- Nov 10, 2026
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 22 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to learn whether an antibiotic-releasing nail placed inside the shinbone (tibia) helps prevent infection and supports bone healing in adults with an open shinbone fracture. The study will test two versions of the Reselution Tibial Intramedullary Fixation System: one that releases vancomycin (Reselution V) and one that releases vancomycin and tobramycin (Reselution VT). The main question it aims to answer is: within 12 months of surgery, how many participants heal without unplanned repeat surgery on the injured leg, have a healed bone on X-ray, and have no serious device-related side effects? Participants will: * Have surgery to fix their shinbone with the Reselution nail * Have blood tests in the first 2 weeks after surgery (this testing may be stopped for later participants after an independent safety review) * Attend follow-up visits for up to 24 months, including X-rays and questionnaires
Conditions
- Tibial Fractures
- Fractures, Open
Interventions
Reselution V Tibial Intramedullary Fixation SystemDevice
Device-led combination product: titanium tibial intramedullary nail with an internal core loaded with vancomycin for local sustained antibiotic delivery.
Reselution VT Tibial Intramedullary Fixation SystemDevice
Device-led combination product: titanium tibial intramedullary nail with an internal core loaded with vancomycin and tobramycin for local sustained antibiotic delivery.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Composite Success at 12 MonthsTime frame: 12 months after surgery
Locations
1 site in 1 country. Site status is shown where the registry gives one.
University of Maryland, Baltimore
Baltimore, Maryland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.